AIFA
- Status: approved
Part B: Multiple-dose ATM-AVI, Cohorts 1-4 (part-b-multiple-dose-atm-avi-cohorts-1-4) regulatory status in Italy.
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. AIFA has authorised it.
Pfizer is the originator. The local marketing authorisation holder may differ — check the official source linked above.